Michael Conick Hanley
No más puestos en curso
Fortuna: 47 017 $ al 30/04/2024
Perfil
Michael Conick Hanley worked as the Chief Business Officer at Spyre Therapeutics, Inc. from 2022 to 2023.
Prior to that, he was the Chief Commercial Officer & Vice President at Esteve Pharmaceuticals S.A.
from 2018 to 2019 and the Group Vice President-Marketing at Horizon Therapeutics Plc from 2015 to 2017.
Hanley completed his undergraduate degree at Notre Dame University and earned an MBA from Kellogg School of Management.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SPYRE THERAPEUTICS, INC
0.00% | 23/02/2023 | 1 448 ( 0.00% ) | 47 017 $ | 30/04/2024 |
Antiguos cargos conocidos de Michael Conick Hanley.
| Empresas | Cargo | Fin |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 14/04/2023 |
Esteve Pharmaceuticals S.A.
 Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 01/09/2019 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Ventas & Marketing | 01/06/2017 |
Formación de Michael Conick Hanley.
| Kellogg School of Management | Masters Business Admin |
| Notre Dame University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Esteve Pharmaceuticals S.A.
Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Conick Hanley
